PTEN deficiency confers sensitivity to ATR inhibitor–based treatment in high-grade serous ovarian cancer
Jie Hao, Bose Kochupurakkal, Timothy B. Branigan, Ozge Somuncu et autres
0 citationsJournal of Clinical Investigation
Lainie P. Martin
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
282Publications signalées
7724Citations signalées
3Affiliations récentes
Institutions déclarées
Domaines associés
Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapyHER2/EGFR in Cancer ResearchCAR-T cell therapy researchEndometrial and Cervical Cancer Treatments
Publications récentes
A phase 1/2 study of REGN5668, a MUC16×CD28 costimulatory bispecific antibody, in combination with other targeted therapies, in patients with recurrent ovarian or endometrial cancer: Trial in progress update.
Roisin Eilish O'Cearbhaill, John W. Moroney, Lainie P. Martin, Jill Tseng et autres
0 citationsJournal of Clinical Oncology
PARPA-293-003: A phase 1a/1b, multicenter, open-label study of NMS-03305293 (itareparib), a non-trapping PARP1-selective inhibitor, in combination with topotecan in patients with recurrent platinum-resistant ovarian cancer
Ravali Reddy, Amir Jazaeri, Shannon Westin, Jeffery Russell et autres
0 citationsGynecologic Oncology
Results of a randomized phase III trial of letrozole alone versus paclitaxel and carboplatin followed by letrozole as initial treatment for patients with stage II-IV ovarian, fallopian tube, or primary peritoneal low-grade serous carcinoma (NRG-GY019, NCT04095364)
Amanda Fader, Austin Miller, Lilian Gien, Amy Deery et autres
4 citationsGynecologic Oncology
Combination ATR and PARP Inhibitor (CAPRI) trial in recurrent platinum-sensitive high-grade serous ovarian cancer demonstrates activity independent of homologous recombination repair status
Fiona Simpkins, Dimitrios Nasioudis, Stéphanie Gaillard, Stephanie L. Wethington et autres
0 citationsGynecologic Oncology
A phase 1/2 study of REGN5668, a MUC16 × CD28 costimulatory bispecific antibody, in combination with other targeted therapies, in patients with recurrent ovarian or endometrial cancer: Trial in progress update
Roisin O'Cearbhaill, Sara Bouberhan, Els Van Nieuwenhuysen, Ira Winer et autres
0 citationsGynecologic Oncology
Approaches to optimize the benefits of immunotherapy and immunotherapy combinations across endometrial cancer types
Bradley R. Corr, Kara D. Romano, Michael Toboni, Katherine C. Fuh et autres
0 citationsJNCI Journal of the National Cancer Institute
A phase 1/2 trial investigating REGN5668, a MUC16×CD28 costimulatory bispecific antibody, in combination with other targeted therapies in patients with recurrent ovarian or endometrial cancer: trial in progress update
Roisin E. O'Cearbhaill, Sara Bouberhan, Els Van Nieuwenhuysen, Ira Winer et autres
0 citationsInternational Journal of Gynecological Cancer
Supplemental Figure S5 from [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
Austin R. Pantel, Sarah B. Gitto, Mehran Makvandi, Hyoung Kim et autres
0 citations
Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
Stephanie L. Wethington, Payal D. Shah, Lainie P. Martin, János L. Tanyi et autres
0 citations
Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
Stephanie L. Wethington, Payal D. Shah, Lainie P. Martin, János L. Tanyi et autres
0 citations
Supplementary Table 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
Stephanie L. Wethington, Payal D. Shah, Lainie P. Martin, János L. Tanyi et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.